FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to oncology, and can be used in treating malignant growths. Methods of the invention involve measuring the concentration of free GPC3 in the serum recovered from the patient before initiating therapy with the anti-GPC3 antibody and/or from the patient undergoing the GPC3 antibody therapy. If the concentration of free GPC3 is equal to or above a predetermined value and/or the concentration of free GPC3 in the serum recovered from the patient, treated with the anti-GPC3 antibody, higher than in serum recovered from said patient suffering from malignant neoplasm to beginning of therapy with anti-GPC3 antibody, it is determined that the above therapy with the antibody against GPC3 is effective or that said therapy with the antibody against GPC3 should be continued.
EFFECT: use of inventions makes it possible to increase efficiency of GPC3-targeted therapy.
22 cl, 10 tbl, 20 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLYPICAN-3 ANTIBODY | 2005 |
|
RU2427588C2 |
| ANTIBODY TO GLYPICAN 3 | 2011 |
|
RU2611751C2 |
| COMBINED THERAPY BASED ON TUMOUR-TARGETED IMMUNOCYTOKINES CONTAINING VARIANT IL-2, AND ANTIBODIES TO HUMAN PD-L1 | 2015 |
|
RU2710354C2 |
| ANTI-MUC1 DRUG CONJUGATE | 2019 |
|
RU2804703C2 |
| USE OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE IN THE TREATMENT OF UROTHELIAL CARCINOMA | 2019 |
|
RU2750817C1 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2774414C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2663123C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| MEDICATION FOR TREATMENT OF LIVER CANCER | 2009 |
|
RU2523897C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | 2019 |
|
RU2798246C2 |
